InvestorsHub Logo
Followers 42
Posts 5506
Boards Moderated 0
Alias Born 01/28/2010

Re: bgrass1 post# 1074

Tuesday, 05/29/2018 11:22:04 AM

Tuesday, May 29, 2018 11:22:04 AM

Post# of 1189
I tend to disagree. I think OvaDx is a good and promising test based on the pre-clinical data. The problem was (is?) the GREED and incompetence shown by the Schenas and the people they associated with to advance the test.

Arrayit gave the OvaDx IP to Avant in 2009 when it was being run by bunch of crooks in Texas and not surprisingly for years the test went nowhere. The Texas group only had one goal in mind: to get rich quickly and didn't really care about the test other than to use it for their financial benefit. They pumped and dumped ARYC stock using OvaDx promise.
As you may recall one of the texans, Robert Rhodes, who was the ex-CEO of Avant when Avant went public, was busted in a lottery rigging scheme in Iowa and was then fired from Avant. That tells you something about their mindset

Avant has been used many times during its existence by different people to issue hundred of millions of Avant shares for their benefit. In the meantime the company goes nowhere. And OvaDx test sits on the shelf as a tool for the con artists.

I hope that the new Avant management turns this sad company around and gets OvaDx to market. Women would benefit from this test that has up to now been taken hostage by the con artists.

Up to now no serious investor has contributed funds to market OvaDx because any real DD on these companies would send them running the other way. The Schenas in 2013 falsely convinced Taub/Zalcberg and others that Arrayit still owned the Ovadx IP and we know how well their $2M investment turned out. Taub/Zalcberg sued Arrayit and the case is still pending.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.